deltatrials

Hormone receptor positive breast carcinoma Trials in Atlanta, United States

Conditions / Hormone receptor positive breast carcinoma / Atlanta, United States

Clinical trials for Hormone receptor positive breast carcinoma investigate a range of treatment strategies and patient populations.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT03845166 A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors ACTIVE_NOT_RECRUITING PHASE1
NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
NCT04316117 Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study ACTIVE_NOT_RECRUITING PHASE2
NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
NCT05568472 Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study ACTIVE_NOT_RECRUITING NA
NCT02003209 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer COMPLETED PHASE3
NCT06112613 Mobile Health for Adherence in Breast Cancer Patients RECRUITING NA
NCT04314401 National Cancer Institute "Cancer Moonshot Biobank" ACTIVE_NOT_RECRUITING

Related Pages